Surgery for Lung Cancer: 356 Real Stories

356 stories match lung cancer and surgery. 177 of them mention chemotherapy.

Cancer Stories

Ashley, who was diagnosed with Stage I Lung AdenocarcinomaLung Cancer

Stage I EGFR Lung Adenocarcinoma: Ashley's Patient Story

Patient Info: Ashley Stringer, Female, Under 40 | Stage I

Biomarkers: EGFR-positive

As of May 2021, Ashley was 4 years from diagnosis after lobectomy and 2 radiation courses, with ongoing monitoring of lung nodules and possible future EGFR-targeted therapy if needed.

MD Anderson
OutcomeCare Ongoing
A patient, who was diagnosed with Non-Small Cell Lung CancerLung Cancer

Immunotherapy and surgery for lung adenocarcinoma with two brain metastases

Patient Info: Anonymized, Female, 50s

Biomarkers: PD-L1 100%; no actionable mutations on next-generation sequencing.

After brain surgery, radiation, 11 cycles of pembrolizumab, and lung surgery, she was off treatment and under observation in remission.

PubMed Central
OutcomeCancer-Free / NED
A patient, who was diagnosed with Lung CancerLung Cancer

Immunotherapy and surgery for adenosquamous lung cancer with brain metastases

Patient Info: Anonymized, Female, 70+

Biomarkers: PD-L1 positive; no actionable mutations on next-generation sequencing.

After chemotherapy, 19 cycles of pembrolizumab, and right middle lobectomy, she was off immunotherapy and under observation in remission.

PubMed Central
OutcomeCancer-Free / NED
A patient, who was diagnosed with Lung AdenocarcinomaLung Cancer

Chemotherapy, immunotherapy, and surgery for lung cancer that spread to the foot

Patient Info: Anonymized, Female, 70+

Biomarkers: PD-L1 20%; no actionable mutations on next-generation sequencing.

She had a significant response after four cycles of chemotherapy and pembrolizumab, and the resected lung nodule contained fibrosis and scar without carcinoma; further systemic treatment and radiation were under consideration.

PubMed Central
OutcomeResponding Well
A patient, who was diagnosed with Stage IV Lung CancerLung Cancer

Pleomorphic Lung Cancer Progressed Despite Pembrolizumab

Patient Info: Anonymized, Male, 70+ | Stage IV

Biomarkers: EGFR-negative; ALK-negative; ROS1-negative; PD-L1 TPS 80%-90%.

Metastatic Site: small intestine; pleura; abdominal subcutaneous tissue

The cancer did not respond to pembrolizumab, and he died four months after immunotherapy began.

PubMed Central
OutcomeIn Memory
A patient, who was diagnosed with Stage IV Lung CancerLung Cancer

Pembrolizumab Controlled Metastatic Pleomorphic Lung Cancer After Chemotherapy Failed

Patient Info: Anonymized, Male, 40s | Stage IV

Biomarkers: EGFR-negative; ALK-negative; ROS1-negative; BRAF-negative; PD-L1 TPS 60%-70%; BRCA2, and TP53 mutations; tumor mutation burden 42 mutations/Mb; no actionable alteration.

Metastatic Site: right adrenal gland; left adrenal gland; bone

Tumor diameter had decreased at 11 months, and pembrolizumab remained ongoing at 12 months.

PubMed Central
OutcomeResponding Well
A patient, who was diagnosed with Lung Squamous Cell CarcinomaLung Cancer

Lung Cancer Metastases to Both Kidneys Causing Kidney Failure

Patient Info: Anonymized, Male, 50s | Stage Metastatic/Advanced

Biomarkers: PD-L1 highly expressed

Metastatic Site: brain|bilateral kidneys|lungs

The cancer progressed in both kidneys and lungs despite treatment, causing dialysis-dependent kidney failure. He later developed severe respiratory illness and died 5 days after readmission.

PubMed Central
OutcomeIn Memory
Rachel, who was diagnosed with Non-Small Cell Lung CancerLung Cancer

Non-Small Cell Lung Cancer: Rachel's Survivor Story

Patient Info: Rachel Chua Bradley, Female, 50s

As of April 2021, Rachel had completed treatment for recurrent non-small cell lung cancer, was not on maintenance cancer medication, and returned to MD Anderson every 6 months for checkups.

MD Anderson
OutcomeSurvivorship / Surveillance
Terri, who was diagnosed with Stage III Non-Small Cell Lung CancerLung Cancer

Stage III KRAS Non-Small Cell Lung Cancer: Terri's Survivor Story

Patient Info: Terri Conneran, Female | Stage III

Biomarkers: KRAS-mutated; PD-L1 level reviewed/tested

As of March 2021, Terri had Stage IIIA KRAS-mutated NSCLC with 3 local recurrences treated over time and had again reached no evidence of disease while continuing close surveillance and advocacy through KRAS Kickers.

The Patient Story
OutcomeCancer-Free / NED
AP
Lung Cancer

A painful scalp metastasis from sarcomatoid lung cancer

Patient Info: Anonymized, Female, 50s | Stage IV

Biomarkers: No targetable mutations identified; CAM5.2-positive; p63-positive; CD10-positive; vimentin-positive.

Metastatic Site: chest wall and rib; liver; right gluteal region; scalp…

Her disease progressed with a further liver lesion and additional metastatic complications, and systemic treatment was stopped because of severe immune-related toxicity and the absence of targetable mutations.

PubMed Central
OutcomeSetback / Progression
A patient, who was diagnosed with Lung CancerLung Cancer

Primary pulmonary adenoid cystic carcinoma found with chronic lymphocytic leukaemia

Patient Info: Anonymized, Male, 50s

Biomarkers: Cytokeratin-positive; SMA-positive; p63-positive; TTF-1-negative; S100-negative; CK20-negative; CD56-negative.

Six months after adjuvant radiation, restaging CT showed treatment-related changes without local or metastatic recurrence.

PubMed Central
OutcomeCancer-Free / NED
A patient, who was diagnosed with Stage IV Lung AdenocarcinomaLung Cancer

Lung adenocarcinoma first detected through an adrenal metastasis

Patient Info: Anonymized, Male, 60s | Stage IV

Biomarkers: No driver mutations identified.

Metastatic Site: left adrenal gland

After resection of the adrenal metastasis, postoperative imaging showed further thoracic uptake and he began palliative chemotherapy for metastatic lung adenocarcinoma without identified driver mutations.

PubMed Central
OutcomeCare Ongoing
A patient, who was diagnosed with Stage IV Lung CancerLung Cancer

Likely lung carcinoma presenting as bilateral adrenal metastases

Patient Info: Anonymized, Male, 70+ | Stage IV

Metastatic Site: bilateral adrenal glands

Three months after bilateral adrenalectomy, he remained under regular oncology surveillance, was receiving steroid replacement, and had not required adjuvant chemotherapy.

PubMed Central
OutcomeCare Ongoing
A patient, who was diagnosed with Stage IV Lung AdenocarcinomaLung Cancer

Stage IV Mucinous Lung Cancer Treated With Afatinib and Surgery

Patient Info: Anonymized, Female, 40s | Stage IV

Biomarkers: CD74-NRG1 fusion; ALK/ROS1/EGFR/BRAF/KRAS/MET/HER2 wild type; PD-L1 initially not expressed and later 0%-20%

Metastatic Site: bilateral lungs|bone|right adrenal gland

She was alive and receiving treatment after bone and right-adrenal progression at the latest follow-up.

PubMed Central
OutcomeCare Ongoing
A patient, who was diagnosed with Lung AdenocarcinomaLung Cancer

Recurrent Mucinous Lung Cancer With Dose-Dependent Afatinib Responses

Patient Info: Anonymized, Female, Under 40 | Stage Metastatic/Advanced

Biomarkers: SDC4-NRG1 fusion; PD-L1 not expressed; low tumor mutation burden

Metastatic Site: bilateral lungs

She had progressive lung disease after several targeted-treatment attempts and was receiving paclitaxel with bevacizumab as of February 2020.

PubMed Central
OutcomeCare Ongoing
A patient, who was diagnosed with Lung AdenocarcinomaLung Cancer

NRG1-Fusion Lung Cancer With a 24-Month Response to Afatinib

Patient Info: Anonymized, Female, 50s | Stage Metastatic/Advanced

Biomarkers: NRG1 fusion; KRAS/EGFR/ALK/ROS1/ERBB2 alterations not detected

Metastatic Site: left lung

Her cancer progressed during atezolizumab, and she died in May 2019.

PubMed Central
OutcomeIn Memory
A patient, who was diagnosed with Stage IV Lung AdenocarcinomaLung Cancer

Surgery for an isolated splenic metastasis from lung adenocarcinoma

Patient Info: Anonymized, Female, 70+ | Stage IV

Metastatic Site: spleen

Nine months after removal of the isolated splenic metastasis, follow-up showed no local or disseminated recurrence and she remained under regular lung-cancer surveillance.

PubMed Central
OutcomeCancer-Free / NED